News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below:
You are invited to attend the first featured presentation in the "State-of-the-Art Topics in Vaccinology" Seminar Series on Tuesday January 28, 2025 at 2 pm. by Dr. Nadine Rouphael, Executive Director of the Hope Clinic at the Emory Vaccine Center.
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.
The GW VRU contributed critical data needed to approve the use of the Mpox vaccine in adolescents. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children in this wave.
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
The CDC has released a new report on the health and economic benefits of routine childhood immunizations since the creation of the Vaccines for Children (VFC) program in 1994.